A recent study found that contraception with depot medroxyprogesterone acetate might increase the risk of diabetes in some Latino women with prior pregnancy related or gestational diabetes.
Dr. Anny Hui Xiang of Reuters Health said that DMPA and breast-feeding or DMPA and high triglycerides were associated with increased risk of diabetes in these women.
Depot medroxyprogesterone (DMPA) contraceptives are given by monthly injections, and are often referred by the brand name, Depo Provera.
The annual incidence rate of diabetes was 19.1 percent in the DMPA group compared with 11.9 percent in the oral contraceptives group.
Adjustment for baseline body weight, breast-feeding rates, and family history reduced the increased risk associated with DMPA use from 58 percent to 18 percent and further adjustment for weight gain during follow-up reduced it further even to 7 percent.
Patients who breast-feed and also have relatively high triglyceride are recommended not to use DMPA, and even if they still elect to use DMPA, blood sugar should be regularly monitored, said Xiang.